
Real-World Effectiveness of Nirsevimab Against Respiratory Syncytial Virus: A Test-Negative Case-Control Study 2024 Hanmeng Xu; Camilla Aparicio; Aanchal Wats; Barbara Araujo; Virginia Pitzer; Joshua Warren PMID: 39314944DOI: https://dx.doi.org/10.1101/2024.09.12.24313545 Access Resources Journal ArticleEN Ask aRCie About This Resource About This article describes a study that evaluated the effectiveness of nirsevimab in preventing RSV infections in infants. It included 3,090 infants and found that nirsevimab provided 68.4% effectiveness against RSV infections. Effectiveness varied by severity, with the highest protection seen in severe cases. Protection lasted for at least three months post-immunization. The study supports the use of nirsevimab to prevent RSV-related outcomes in infants. Tags Focus Area: Infectious Disease Audiences: Nurses; Physicians Emergency Management Stages: Response; Preparedness (Prevention / Protection) Bundles: Nirsevimab Library Keywords: Hospitalization; Infant; Inpatients; Outpatients; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Immunization Programs; Antibodies, Monoclonal, Humanized Institutions: Yale School of Medicine; Yale University More like this Parent Perspectives on Nirsevimab for Their Newborn 2024 · Yale School of Medicine, Yale University Factors Associated With Nirsevimab Uptake in Healthy Newborns 2024 · Yale School of Medicine, Yale University Early Experiences With Nirsevimab: Perspectives From Newborn Hospitalists 2024 · Yale School of Medicine, Stanford University, Seattle Children's Hospital, The University of Chicago Medicine, Nationwide Children's Hospital, Yale University The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Access Resources Journal ArticleEN Ask aRCie About This Resource

Real-World Effectiveness of Nirsevimab Against Respiratory Syncytial Virus: A Test-Negative Case-Control Study

2024
Hanmeng Xu; Camilla Aparicio; Aanchal Wats; Barbara Araujo; Virginia Pitzer; Joshua Warren

PMID: 39314944DOI: https://dx.doi.org/10.1101/2024.09.12.24313545

Access Resources

About

This article describes a study that evaluated the effectiveness of nirsevimab in preventing RSV infections in infants. It included 3,090 infants and found that nirsevimab provided 68.4% effectiveness against RSV infections. Effectiveness varied by severity, with the highest protection seen in severe cases. Protection lasted for at least three months post-immunization. The study supports the use of nirsevimab to prevent RSV-related outcomes in infants.

More like this

Parent Perspectives on Nirsevimab for Their Newborn 2024 · Yale School of Medicine, Yale University Factors Associated With Nirsevimab Uptake in Healthy Newborns 2024 · Yale School of Medicine, Yale University Early Experiences With Nirsevimab: Perspectives From Newborn Hospitalists 2024 · Yale School of Medicine, Stanford University, Seattle Children's Hospital, The University of Chicago Medicine, Nationwide Children's Hospital, Yale University

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Real-World Effectiveness of Nirsevimab Against Respiratory Syncytial Virus: A Test-Negative Case-Control Study

Access Resources

About

Tags

More like this

Access Resources